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General splicing factor SF2/.ASF promotes 
alternative splicing by binding 
to an exonic splicing enhancer 
Qiang Sun, 1 Aki la Mayeda, 2 Robert K. Hampson,  1 Adrian R. Krainer, 2 and Fritz M. Rot tman 1'3 
Department ofMolecular Biology and Microbiology, Case Western Reserve University, School of Medicine, Cleveland, Ohio 
44106-4960 USA; 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724-2208 USA 2 
The general splicing factor SF2/ASF binds in a sequence-specific manner to a pm~ne-dch exonic splicing 
enhancer {ESE) in the last exon of bovine growth hormone (bGH) pre-mRNA. More importantly, SF2/ASF 
stimulates in vitro splicing of bGH intron D through specific interaction with the ESE sequences. However, 
another general splicing factor, SC35, does not bind the ESE sequences and has no effect on bGH intron D 
splicing. Thus, one possible function of SF2/ASF in alternative and, perhaps, constitutive pre-mRNA splicing 
is to recognize ESE sequences. The stimulation of bGH intron D splicing by SF2/ASF is counteracted by the 
addition of hnRNP A1. The relative levels of SF2/ASF and hnRNP A1 influence the fficiency of bGH intron 
D splicing in vitro and may be the underlying mechanism of this alternative pre-mRNA processing event in 
vivo. 
[Key Words: Alternative splicing; bovine growth hormone pre-mRNA; SF2/ASF; hnRNP A1; exonic splicing 
enhancer] 
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Pre-mRNA splicing requires accurate selection of 5' and 
3' splice sites. For many genes, alternative splice sites 
can be selected from a single primary transcript to gen- 
erate two or more mRNAs encoding multiple protein 
isoforms. Although alternative pre-mRNA splicing pro- 
vides an important route for the regulation of gene ex- 
pression, the underlying regulatory mechanisms remain 
largely uncharacterized. 
A central question in constitutive and alternative pre- 
mRNA splicing concems the selection of specific splice 
sites. Introns are defined by the presence of a conserved 
5' splice site, a 3' splice site, a polypyrimidine tract, and 
a less well-conserved branch site. Although these signals 
are required for splicing, they are insufficient o specify 
all introns. Several studies have shown that exon se- 
quences can also play an important role in splice site 
selection {Reed and Maniatis 1986; Mardon et al. 1987; 
Helfman et al. 1988; Cooper and Ordahl 1989; Hampson 
et al. 1989; Kakizuka et al. 1990; Katz and Skalka 1990; 
Libri et al. 1991; Nagoshi and Baker 1990; Hedley and 
Maniatis 1991; Hoshijima et al. 1991; Cooper 1992; Cote 
et al. 1992; Watakabe t al. 1993; Xu et al. 1993}. Al- 
though the precise role of these exon sequences in splic- 
ing remains unclear, recent studies on the Drosophila 
sex determination pathway suggest a possible function 
for such sequences. Alternative splicing of double-sex 
(dsx) pre-mRNA involves utilization of two mutually ex- 
3Corresponding author. 
clusive exons. Sequences in exon 4 regulate its inclusion 
positively in female-specific dsx mRNA (Nagoshi and 
Baker 1990; Hedley and Maniatis 1991; Hoshijima et al. 
1991}. The trans-acting factors encoded by the trans- 
former (tra) and transformer 2 (tra2) genes together acti- 
vate the 3' splice site upstream of the dsx female-specific 
exon 4 through interaction with six 13-nucleotide re- 
peats present in the exon (Tian and Maniatis 1992). 
Thus, protein factors are capable of binding to exon se- 
quences in a sequence-specific manner and affecting 
splicing of introns located some distance away from the 
protein-binding sites. 
A number of factors required for constitutive splicing 
have been shown to be involved in alternative splice site 
selection. The product of the Sex-lethal (Sxl) gene regu- 
lates alternative splicing of tra pre-mRNA by repressing 
the inclusion of exon 2 (Boggs et al. 1987). Recent results 
showed that Sx/inhibits the use of the 3' splice site 
upstream of exon 2 by blocking the binding of the essen- 
tial splicing factor U2AF to the polypyrimidine tract 
(Valcarcel et al. 1993). Binding of U1 small nuclear ibo- 
nucleoprotein (snRNP) to a pseudo-5' splice site, as op- 
posed to the authentic 5' splice site, has been implicated 
in the regulated alternative intron retention of Droso- 
phila P-element pre-mRNA in somatic ells (Siebel et al. 
1992). Both U2AF and U1 snRNPs have been implicated 
in exon definition interactions that specify splicing of 
alternative xon 4 of preprotachykinin (Hoffman and 
Grabowski 1992). 
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SF2/ASF binds to an exonic splicing enhancer 
Two protein factors, SF2/ASF and heterogeneous ribo- 
nucleoprotein {hnRNP) A1, counteract each other in a 
concentration-dependent manner to define alternative 5' 
splice site selection, as well as exon skipping and inclu- 
sion, of a variety of pre-mRNAs in vitro (Ge and Manley 
1990; Krainer et al. 1990b; Mayeda and Krainer 1992; 
Mayeda et al. 1993). SF2/ASF, as well as SC35, can also 
influence alternative 3' splice site selection in vitro (Fu 
et al. 1992}. Both SF2/ASF and SC35 belong to the SR 
{Ser- and Arg-rich) protein family, a group of highly con- 
served nuclear phosphoproteins {Fu et al. 1992; Mayeda 
et al. 1992; Zahler et al. 1992). SR proteins appear to have 
redundant or overlapping, but in some cases, distinct, 
functions in constitutive and alternative pre-mRNA 
splicing (Fu et al. 1992; Kim et al. 1992; Mayeda et al. 
1992; Zahler et al. 1992). These studies suggest hat the 
relative amounts of SR proteins in different cell or tissue 
types may help to determine splice site selection. The 
precise molecular mechanisms by which these factors 
participate in constitutive and alternative splicing re- 
main to be characterized. 
The last intron (intron D) of bovine growth hormone 
(bGH) pre-mRNA is alternatively spliced in the pitu- 
itary, where a small fraction of the cytosolic bGH 
mRNA retains intron D (Hampson and Rottman 1987). 
The identical pattem of alternative intron retention has 
also been conserved in human growth hormone pre- 
mRNA (Cooke et al. 1988). Splicing of bGH intron D is 
dependent on the downstream l l5-nucleotide FP ele- 
ment, a purine-rich exonic splicing enhancer {ESE), both 
in transfected cells and in vitro (Hampson et al. 1989; 
Sun et al. 1993). A competition assay revealed that the 
influence of the FP element on splicing of the upstream 
bGH intron D is mediated through interaction with one 
or more trans-acting factors. A UV cross-linking assay 
identified a 35-kD protein factor that binds specifically 
to the FP element (Sun et al. 1993). In the work reported 
here, we have characterized this 35-kD protein factor 
and found it to be the general splicing factor SF2/ASF. 
SF2/ASF promotes splicing of bGH intron D through 
specific interaction with the FP element in bGH termi- 
nal exon 5. SC35, which has equivalent in vitro splicing 
activities, has no effect on bGH intron D splicing. Fur- 
thermore, the positive influence of SF2/ASF on the splic- 
ing of bGH intron D can be counteracted by hnRNP A1 
protein. 
Resu l ts  
The 35-kD protein factor that binds specifically 
to the FP element is absent in HeLa cell SIO0 extracts 
Previous work showed that a 35-kD protein factor{s) 
binds specifically to the FP element in bGH terminal 
exon 5 (Sun et al. 1993). To further characterize this pu- 
tative 35-kD protein factor{s), two RNA substrates were 
made. E5/FP RNA is a 127-nucleotide T7 RNA polymer- 
ase runoff transcript containing the l l5-nucleotide FP 
element and 12 additional nucleotides of vector se- 
quence. ES/FPD RNA is a 147-nucleotide T7 transcript 
that lacks the FP element and contains instead a 135- 
nucleotide sequence of bGH exon 5 plus the same 12- 
nucleotide vector sequence present in E5/FP RNA {Fig. 
1A). The E5/FP RNA employed in these experiments i
identical to the FP1 RNA used in previous studies (Sun 
et al. 1993) except hat the E5/FP RNA lacks 47 nucle- 
otides of vector sequence. When radiolabeled ES/FP 
RNA was UV cross-linked in HeLa cell nuclear extract, 
both in the presence and absence of ATP and Mg 2+, two 
major cross-linked bands of 55 and 35 kD were observed 
{Fig. 1B, lanes 3,4}. The appearance of both cross-linked 
bands was dependent on addition of nuclear extract {Fig. 
Figure 1. Characterization f the 35-kD protein factor(s). (A) 
RNA substrates used for in vitro splicing reactions and UV 
cross-linking assays. Solid areas denote the FP element; lightly 
shaded areas denote other exon 5 sequences excluding the FP 
element. {B) UV cross-linking of a2P-labeled ES/FP and ES/FPD 
RNA in HeLa cell nuclear extract (N.E.) or $100 extract (S100). 
UV irradiation, additions of ATP and Mg 2 + {ATP/Mg), N.E., and 
S100 are indicated by plus (+1 d.rid minus { - ) signs. The cross- 
linked material was analyzed by SDS-PAGE after RNase A 
treatment, as described ia.Materials and methods. (C) Cross- 
linking of the 35-kD protein(s) to E5/FP RNA in nuclear extrat;t 
is competed by increasing amounts of unlabeled ES/FP RNA, 
but not by E5/FPD RNA. (Lane 1) no competitor was added. 
Molar excess (4-, 7.5-, 15-, and 30-fold) of unlabeled ES/FP RNA 
(lanes 2-5) or unlabeled ES/FPD RNA (lanes 6--9} was added at 
the same time as the labeled E5/FP RNA. Protein standards are 
low-range prestained markers (Bio-Rad). 
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1B, lane 1) and UV irradiation (Fig. 1B, lane 2). When 
radiolabeled ES/FP RNA was cross-linked in HeLa cell 
$100 extract, however, only the 55-kD and a new 65-kD 
cross-linked band were observed, both in the presence 
and absence of ATP and Mg 2+ (Fig. 1B, lanes 5,6}. Thus, 
the cross-linked 35-kD polypeptide present in nuclear 
extract appears to be absent from $100 extract. 
To confirm the binding specificity of this 35-kD pro- 
tein(s) to the FP sequence in bGH exon 5, RNA lacking 
the FP element (E5/FPD) was used in UV cross-linking 
assays. We hypothesized that if the binding of this 35-kD 
protein(s} is specific, the protein should only recognize 
E5/FP RNA, but not E5/FPD RNA, because xon 5 lack- 
ing the FP element is unable to activate splicing of the 
upstream bGH intron D. When radiolabeled E5/FPD 
RNA was cross-linked in HeLa cell nuclear extract, ei- 
ther in the presence or absence of ATP and Mg a +, only a 
trace of 35-kD cross-linked protein could be detected 
{Fig. 1B, lanes 7,8}, further suggesting that binding of the 
35-kD protein(s) to the FP element is sequence specific. 
Binding of the 35-kD protein(s) to E5/FPD RNA was not 
detected in HeLa cell $100 extract under similar condi- 
tions {Fig. 1B, lanes 9,10}. The 55-kD protein, which was 
previously shown to bind nonspecifically, cross-linked 
to E5/FPD RNA under all conditions tested (Fig. 1B, 
lanes 7-10). Finally, the cross-linking of the 35-kD pro- 
tein{s) to ES/FP RNA was competed by increasing 
amounts of unlabeled ES/FP RNA {Fig. 1C, lanes 2-5}, 
but not by unlabeled E5/FPD RNA (Fig. 1C, lanes 6-9). 
The observed selectivity ratio between these RNAs was 
greater than 10. Therefore the 35-kD polypeptide(s), but 
not the 55-kD polypeptide(s}, binds specifically to the FP 
element in bGH terminal exon 5. 
The general splicing factor SF2/ASF binds 
specifically to the FP element 
The absence in HeLa cell S100 extracts of the 35-kD 
protein factor(s} that binds specifically to the FP element 
suggests that it might be one of the SR proteins. These 
proteins are part of a conserved family of splicing factors 
with related biochemical activities, which are present in 
trace amount in S100 extracts {Fu et al. 1992; Kim et al. 
1992; Mayeda et al. 1992; Zahler et al. 1992, 1993}. SF2/ 
ASF, a member of the SR family, migrates as a doublet of 
-33 kD on SDS-PAGE and is required for pre-spliceo- 
some complex formation (Krainer et al. 1990a). Deletion 
of the FP element, the binding site for the putative 35-kD 
protein factor(s), from the bGH terminal exon 5, blocks 
splicing at an early step, that is, at or before pre-spliceo- 
some complex assembly (Sun et al. 1993}. A UV cross- 
linking/immunoprecipitation assay was performed to 
determine whether the 35-kD protein(s) that cross-links 
specifically to the FP element is SF2/ASF. Anti-SF2/ASF 
monoclonal antibody (mAb) specifically precipitated a
labeled 35-kD protein when the E5/FP RNA was cross- 
linked in HeLa cell nuclear extract, either in the pres- 
ence or absence of ATP and Mg 2+ {Fig. 2A, lanes 2,31. 
The labeled 55-kD protein(s}, which binds nonspecifi- 
cally to E5/FP RNA, was not precipitated by anti-SF2/ 
Figure 2. SF2/ASF binds specifically to the FP element. (A) 
lmmunoprecipitation of a 35-kD protein bound specifically to 
the FP element with anti-SF2/ASF mAb. (Lane 1) Cross-linking 
of E5/FP RNA in HeLa cell nuclear extract (N.E.} without im- 
munoprecipitation; {lanes 2-6) cross-linking of RNA and pro- 
tein followed by immunoprecipitation with monoclonal anti- 
bodies as described in Materials and methods. A ditions of ATP 
and Mg ~+ (ATP/Mg), N.E., $100, and monoclonal antibodies 
{Ab) specific for SF2/ASF (a-SF2) or a control bacterial protein 
{Cont) are indicated by plus ( + ) and minus ( - } signs. {B) Purified 
SF2/ASF cross-links to ES/FP RNA, but not o ES/FPD RNA. 
{+ and -) Additions of ATP/Mg, N.E., and 0.4 ~g of purified 
SF2/ASF protein (pSF2}. {C) Cross-linking of SF2/ASF to E5/FP 
RNA is competed by increasing amounts of unlabeled E5/FP 
RNA, but not by E5/FPD RNA. Each reaction contained 0.4 ~g 
of purified SF2/ASF protein and 7 ~g of BSA. {Lane 1} No com- 
petitor was added. Unlabeled E5/FP RNA (4-, 7.5-, 15-, and 30- 
fold molar excess) {lanes 2-5) or unlabeled ES/FPD RNA {lanes 
6-9) was added at the same time as the labeled E5/FP RNA. 
Protein standards are as in Fig. 1. 
ASF mAb. The labeled 35-kD protein(s) was not precip- 
itated by a control monoclonal antibody (Fig. 2A, lane 5), 
nor was it detected in anti-SF2/ASF mAb immunopre- 
cipitates when E5/FP RNA was cross-linked in HeLa cell 
S100 extracts (Fig. 2A, lane 4}, or when ES/FPD KNA 
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was cross-linked in HeLa cell nuclear extracts (Fig. 2A, 
lane 6). Because anti-SF2/ASF mAb did not quantita- 
tively precipitate ither the cross-linked 35-kD band or 
purified SF2/ASF protein (data not shown), we could not 
address whether SF2/ASF is the only 35-kD protein that 
specifically binds to the FP element in nuclear extracts. 
Cross-linking of a 35-kD protein(s) to E5/FP RNA, but 
not to E5/FPD RNA, was observed in HeLa cell S100 
extracts complemented with purified human SF2/ASF 
protein (data not shown). This observation is consistent 
with SF2/ASF being the 35-kD ES/FP RNA-binding pro- 
tein that is present in trace amounts in S 100 extracts. We 
then examined whether specific binding to the FP ele- 
ment is an intrinsic property of SF2/ASF or whether in- 
teractions with other components are required. UV 
cross-linking experiments were carried out with purified 
HeLa cell SF2/ASF, in the absence of S100 extract. E5/FP 
RNA cross-linked to purified SF2/ASF, either in the 
presence or absence of ATP and Mg 2+ (Fig. 213, lanes 2,3}. 
The electrophoretic mobilities of the 35-kD protein in 
nuclear extract and purified SF2/ASF after cross-linking 
to E5/FP RNA were identical (Fig. 2B, cf. lanes 1-3). 
ES/FPD RNA, however, did not cross-link to purified 
SF2/ASF under similar conditions (Fig. 2B, lanes 4,5). 
The cross-linking of SF2/ASF to E5/FP RNA could be 
competed by increasing amounts of unlabeled E5/FP 
RNA (Fig. 2C, lanes 1-5), and only slightly by ES/FPD 
RNA (Fig. 2C, lanes 6-9), further indicating that SF2/ 
ASF is capable of specifically recognizing the FP element 
in the absence of other factors. The observed selectivity 
ratio of purified SF2/ASF for ES/FP versus ES/FPD RNA 
was >10, similar to that observed for the 35-kD protein 
in nuclear extract. 
SF2/ASF promotes plicing of bGH intron D 
through specific interaction with the FP element 
in the downstream exon 
It is important to determine whether SF2/ASF binding to 
the FP element is functionally significant, that is, capa- 
ble of activating the splicing of upstream intron D. When 
the wild-type bGH pre-mRNA substrate, pbGH-4D5 
{Fig. 1A), was spliced in HeLa cell nuclear extract, addi- 
tion of purified SF2/ASF stimulated the splicing of bGH 
intron D (Fig. 3A, cf. lanes 1 and 2). Splicing of bGH 
intron D was inhibited by a 10-fold molar excess of un- 
labeled ES/FP specific competitor RNA (Fig. 3A, lane 3) 
but not by a 100-fold molar excess of E5/FPD nonspecific 
competitor RNA {Fig. 3A, lane 4). When both specific 
competitor (ES/FP RNA) and purified SF2/ASF were 
added to the same reaction, SF2/ASF relieved the inhi- 
bition of splicing (Fig. 3A, lane 5, cf. lane 3), presumably 
by compensating for the loss of endogenous SF2/ASF ti- 
trated by the added E5/FP RNA. The stimulation of bGH 
intron D splicing by SF2/ASF is -5-  to 10-fold, which is 
comparable to the SF2/ASF selectivity ratio in the bind- 
ing assays. This result suggests that the SF2/ASF binding 
to the FP element has functional significance and is re- 
sponsible for activation of intron D splicing. Addition of 
SF2/ASF to reactions containing the mutant bGH pre- 
Figure 3. SF2/ASF promotes splicing of bGH intron D through 
specific interaction with the FP element. {A) SF2/ASF stimu- 
lates plicing of bGH intron D. Pre-mRNA substrate pbGH-4D5 
was spliced in nuclear extract for90 mill. ( + and - ) Additions 
of 10-fold molar excess of E5/FP RNA, 100-fold molar excess of 
E5/FPD RNA, and 0.4 wg of purified human SF2/ASF protein 
(pSF2). (B) SF2/ASF fails to activate splicing of bGH mutant 
pre-mRNA lacking the FP element. Pre-mRNA substrate 
pbGH-4DS/FPD was incubated under splicing conditions in nu- 
clear extract for 90 rain in the absence (lane 1) or the presence 
(lane 21 of 0.4 ~g of purified human SF2/ASF (pSF2). Pre-mRNA, 
spliced products, and intermediates are indicated by diagrams. 
The molecular size markers (lane M) are pBR322 digested with 
HpalI. 
mRNA substrate pbGH-4DS/FPD (Fig. 1A), however, 
had no effect on splicing of bGH intron D (Fig. 3B, lanes 
1,2), that is, splicing was undetectable r gardless of the 
addition of SF2/ASF. Therefore, the FP element in the 
downstream exon, which interacts specifically with SF2/ 
ASF, is required for activation of intron D splicing by 
SF2/ASF. 
SC35 cannot be not cross-linked to the FP element 
in the downstream exon and does not stimulate 
bGH intron D splicing 
The SF2/ASF protein used in the experiments described 
f 
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earlier was a highly purified preparation from HeLa cells. 
To rule out the possibility that specific binding and 
splicing activation are attributable to trace contaminat- 
ing proteins in the SF2/ASF preparation, the experi- 
ments were repeated with purified recombinant SF2/ 
ASF (Caceres and Krainer 1993). Recombinant SF2/ASF 
has a somewhat lower specific activity than I-IeLa cell 
SF2/ASF as shown by complementation f S100 extract 
for splicing of adenovirus and [3-globin pre-mRNA sub- 
strates (data not shown). This is probably attributable to 
the required renaturation procedure and/or to the lack of 
post-translational modifications {Caceres and Krainer 
1993). When recombinant SF2/ASF was used in the UV 
cross-linking assay, it bound to E5/FP RNA in the pres- 
ence or absence of ATP and Mg ~+ (Fig. 4A, lanes 6,7) and 
much more weakly to ES/FPD RNA under similar con- 
ditions (Fig. 4A, lanes 8,9). When wild-type bGH pre- 
mRNA (pbGH-4DS) was spliced in HeLa cell nuclear ex- 
tract, addition of recombinant SF2/ASF also stimulated 
splicing of bGH intron D (Fig. 4B, of. lanes 1 and 4). Thus, 
recombinant SF2/ASF exhibited similar RNA-binding 
specificity and bGH splicing stimulatory activity as the 
highly purified HeLa cell SF2/ASF, confirming that SF2/ 
ASF promotes plicing of bGH intron D through specific 
interaction with the downstream exonic FP element. 
SG35, another SR protein of similar size, has been re- 
ported to have very similar in vitro splicing activities to 
those of SF2/ASF (Fu et al. 1992). We therefore tested 
whether SC35 can also activate bGH intron D splicing. 
When recombinant SC35 was used in the UV cross-link- 
ing assay, it cross-linked neither to ES/FP RNA nor to 
ES/FPD RNA (Fig. 4A, lanes 2-5). When wild-type bGH 
pre-mRNA was spliced in HeLa cell nuclear extract, ad- 
dition of recombinant SC35 had no effect on splicing of 
bGH intron D (Fig. 4B, cf. lanes 1 and 3). However, the 
same preparation of recombinant SC35 had higher gen- 
eral splicing activity than recombinant SF2/ASF when 
identical amounts of both recombinant proteins 'were 
tested in the S100 complementation assay with an ade- 
novirus pre-mRNA substrate (data not shown) and a 
f~-globin pre-mRNA substrate (Fu et al. 1992). Therefore, 
in contrast to SF2/ASF, SC35 does not interact specifi- 
cally with the FP element and does not promote splicing 
of bGH intron D. 
hnRNP A1 counteracts the activation of bGH 
intron D splicing by SF2/ASF 
Heterogeneous ribonucleoprotein {hnRNP) A1 has been 
shown to counteract the effect of SF2/ASF in alternative 
splicing events involving 5' splice site selection and 
exon skipping or inclusion, but not 3' splice site selec- 
tion {Fu et al. 1992; Mayeda nd Krainer 1992; Mayeda et 
al. 1993}. It was of interest to determine whether hnRNP 
A1 also counteracts SF2/ASF in alternative intron reten- 
tion. Addition of recombinant hnRNP A1 protein to the 
in vitro splicing reaction inhibited splicing of bGH in- 
tron D {Fig. 5, cf. lanes 1 and 2). Moreover, further addi- 
tion of SF2/ASF reversed the inhibitory effect of hnRNP 
A1 and restored splicing of bGH intron D {Fig. 5, cf. lanes 
2-4}. As shown above, SF2/ASF relieved the inhibition of 
bGH intron D splicing by the specific competitor E5/FP 
RNA {Fig. 3A, lanes 3,5; Fig. 5, lanes 5,9}. However, ad- 
dition of either hnRNP A1 alone or a combination of 
SF2/ASF and hnRNP A1 failed to relieve the inhibition 
of bGH intron D splicing by E5/FP RNA {Fig. 5, lanes 
7,8). In the presence of the nonspecific ompetitor E5/ 
FPD RNA, the effect of hnRNP A1 was similar to that 
without addition of any competitor RNA {Fig. 5, cf. lanes 
2-4 and 10-121. Thus, hnRNP A1 counteracts the stim- 
Figure 4. SC35 does not bind to the FP 
element or stimulate splicing of bGH in- 
tron D. (A) Recombinant SF2/ASF, but not 
recombinant SC35, protein binds specifi- 
cally to E5/FP RNA. (+ and -) Additions 
of ATP/Mg, HeLa cell nuclear extract 
(N.E.), E5/FP or E5/FPD RNAs, 1.3 lag of 
recombinant SF2/ASF(rSF2) and 0.3 lag of 
recombinant SC35 (rSC35). Protein stan- 
dards are as in Fig. 1. {B} Recombinant SF2/ 
ASF, but not recombinant SC.35, activates 
splicing of bGH intron D. Pre-mRNA sub- 
strate pbGH-4D5 was incubated under 
splicing conditions i  nuclear extract for90 
rain in the absence {lane 1) or the presence 
of 0.6 lag of purified human SF2/ASF (pSF2, 
lane 2), 0.4 lag of recombinant SC35 {rSC35, 
lane 3), and 2 Ixg of recombinant SF2/ASF 
(rSF2, lane 4). Pre-mRNA, spliced product, 
and intermediates are indicated by dia- 
grams. The molecular size markers (laneM) 
are pBR322 digested by HpalI. 
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was cross-linked in nuclear extract (Fig. 6A, lanes 3,4}. 
This 35-kD protein was not immunoprecipitated in nu- 
clear extract by a control monoclonal antibody {Fig. 6A, 
lane 7). UV cross-linking of E5/FP RNA in HeLa cell 
$100 extract, followed by anti-hnRNP A1 monoclonal 
antibody immunoprecipitation yielded only a small 
Figure 5. hnRNP A1 counteracts the positive effect of SF2/ 
ASF on splicing of bGH intron D. Pre-mRNA substrate pbGH- 
4D5 was spliced in HeLa cell nuclear extract for 90 min. ( + and 
- J  Additions of 10-fold molar excess of E5/FP RNA, 100-fold 
molar excess of ES/FPD RNA, 0.8 wg of recombinant hnRNP A1 
{rA1), and 0.4 ~g of purified SF2/ASF (pSF2J. Pre-mRNA, spliced 
products, and intermediates are indicated by diagrams. The mo- 
lecular size markers (lane M) are pBR322 digested with HpalI. 
ulatory effect of SF2/ASF on splicing of bGH intron D. 
hnRNP A1 does not have a general splicing inhibitory 
activity in the amounts used here, as it had little effect 
on splicing of control adenovirus (data not shown) and 
B-globin (Mayeda and Krainer 1992) pre-mRNAs. More- 
over, comparable amounts of the same preparation 
switched alternative 5' splice site util ization without re- 
ducing overall splicing (Mayeda and Krainer 1992). 
hnRNP A1 binds with low specificity to the FP element 
Because hnRNP A1 counteracts the stimulatory activity 
of SF2/ASF on splicing of bGH intron D, it was of inter- 
est to determine whether hnRNP A1 also specifically 
recognizes the FP element. Anti-hnRNP A 1 mAb immu- 
noprecipitated a labeled 35-kD protein when E5/FP RNA 
Figure 6. hnRNP A1 binds with low specificity to the FP ele- 
ment. (A) Immunoprecipitation f a 35-kD protein that binds 
both E5/FP and ES/FPD RNA with anti-hnRNP A1 mAb. 
(Lanes 1,: .~ UV cross-linking of E5/FP RNA in HeLa cell nuclear 
extract (N.E.) and S IO0 extract (S 100) without immunoprecipi- 
tation; (lanes 3--7) cross-linking of RNA and protein followed by 
immunoprecipitation with monoclonal antibodies as described 
in Materials and methods. (+ and - )  Additions of ATP/Mg, 
N,E., $100, and monoclonal antibodies (Ab) specific for hnRNP 
A1 {c~-A1) or a bacterial protein (Cont). (B) Recombinant hnRNP 
A1 protein binds to both E5/FP and E5/FPD RNA. { + and - ) 
Additions of ATP/Mg, N.E., and 0.4 ~g of recombinant hnRNP 
A1 (rA1). {C) Cross-linking of hnRNP A1 to E5/FP RNA can be 
competed by both unlabeled E5/FP and E5/FPD RNA. Each 
reaction contained 0.4 ~g of recombinant hnRNP A1 and 7 ~g of 
BSA. (Lane 1) No competitor was added. Molar excess (7.5-, 15-, 
and 30-fold} of unlabeled E5/FP RNA (lanes 2-4) or unlabeled 
E5/FPD RNA (lanes 5-7) was added together with labeled E5/FP 
RNA. Protein standards are as in Fig. 1. 
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amount of 35-kD protein (Fig. 6A, lane 5). This band was 
only visible after long exposure times (data not shown), 
perhaps reflecting the fact that hnRNP A 1 levels in S 100 
extracts are much lower than in nuclear extracts 
(Mayeda et al. 1993). When ES/FPD RNA was cross- 
linked in HeLa cell nuclear extract, anti-hnRNP A1 mAb 
also precipitated the labeled 35-kD protein (Fig. 6A, lane 
6), suggesting that although nRNP A1 binds to the FP 
element, it also binds to other exon 5 sequences. 
To address further the binding specificity of hnRNP 
A1, purified recombinant hnRNP A1 protein was used in 
UV cross-linking experiments. Recombinant hnRNP A1 
was cross-linked to E5/FP RNA, either in the presence or 
absence of ATP and Mg 2+ (Fig. 6B, lanes 2,3). Recombi- 
nant hnRNP A1 protein also cross-linked to E5/FPD 
RNA under similar conditions (Fig. 6B, lanes 4,5), al- 
though with slightly lower efficiency. This was con- 
firmed further by a competition assay in which the cross- 
linking of recombinant hnRNP A1 to labeled ES/FP 
RNA was measured in the presence of increasing 
amounts of unlabeled E5/FP RNA or ES/FPD RNA. Both 
RNA sequences decreased hnRNP A1 binding to the la- 
beled ES/FP RNA, although unlabeled ES/FP RNA com- 
peted slightly better (Fig. 6C). Compared with SF2/ASF, 
hnRNP A 1 binds to the FP element in the bGH terminal 
exon with substantially ower specificity. The observed 
selectivity ratio for binding to the two RNAs was ap- 
proximately 2. 
Discuss ion  
In this study we have demonstrated that the general 
splicing factor SF2/ASF binds specifically and directly to 
the FP element, a purine-rich ESE, in the bGH 3' termi- 
nal exon. This specific protein-RNA interaction results 
in activation of splicing of the preceding bGH intron D. 
However, the related SR protein SC35 does not have the 
same effect on bGH intron D splicing as SF2/ASF. Fur- 
thermore, we have shown that hnRNP A1 counteracts 
the positive influence of SF2/ASF on the splicing of bGH 
intron D. 
Expression of a transiently transfected bGH gene in 
several different cell lines, including COS 1, HeLa, NIH- 
3T3, and CHO, consistently results in the presence of 
-5% intron D-containing bGH mRNA species on poly- 
somes (R.K. Hampson, unpubl.). The range of cell types 
producing this low level of alternatively spliced mRNA 
argues for the involvement of constitutive, rather than 
tissue-specific, splicing factor(s). Immunoprecipitation 
with anti-SF2/ASF mAb showed that the 35-kD protein 
factor(s) includes the general splicing factor SF2/ASF. 
However, we were not able to address whether SF2/ASF 
is the only 35-kD protein in HeLa cell nuclear extracts 
that binds specifically to the FP element, because anti- 
SF2/ASF mAb did not quantitatively precipitate ither 
the 35-kD labeled band or purified SF2/ASF. Anti-SF2/ 
ASF mAb immunoprecipitated SF2/ASF in nuclear ex- 
tract or in purified form with similar, albeit low, effi- 
ciency, suggesting that most of the 35-kD protein that 
binds to the FP element in HeLa cell nuclear extract is 
SF2/ASF. However, the immunoprecipitation experi- 
ments with anti-hnRNP A1 mAb suggest hat other 35- 
kD proteins may also bind to the FP element with un- 
determined levels of specificity. 
Experiments with recombinant SF2/ASF confirmed 
that this factor is responsible for stimulating bGH intron 
D splicing by binding specifically and directly to the ESE. 
In contrast, recombinant SC35 that was highly active in 
S100 complementation assays with f~-globin and adeno- 
virus pre-mRNA substrates was unable to bind directly 
to the ESE or to activate bGH intron D splicing. These 
results demonstrate hat the observed ffects of SF2/ASF 
on bGH intron D splicing are not a simple reflection of 
general splicing stimulation. 
Although previous results indicated that the general 
splicing factor SF2/ASF has general RNA-binding activ- 
ity [e.g., binding to sense and antisense pre-mRNA or 
mRNA (Krainer et al. 1990a; data not shown)], these ex- 
periments did not exclude the existence of high-affinity 
sequence-specific binding sites. Our present results 
clearly indicate that SF2/ASF has a higher binding affin- 
ity for the FP element over other bGH exon 5 sequences, 
with a selectivity ratio >10. This binding preference is
significant because only the FP element, and not the 
other downstream exon 5 sequences, is capable of acti- 
vating splicing of the upstream bGH intron D. These 
results strongly suggest that SF2/ASF promotes the 
splicing of bGH intron D through specific interaction 
with the FP element in the downstream exon 5. Al- 
though we do not as yet know the precise sequences 
within the l lS-nucleotide FP element hat are recog- 
nized by SF2/ASF, recent transfection studies have 
shown that purine-rich elements within the FP sequence 
function as cis-acting signals for splicing activation of 
the upstream bGH intron D, which contains a weak 5' 
splice site {Dirksen et al. 1994). Purine-rich exon se- 
quences have also been reported to be involved in alter- 
native or constitutive splicing of several other pre-mR- 
NAs (Watakabe t al. 1993; Xu et al. 1993). It will be of 
interest to determine whether the general splicing factor 
SF2/ASF and perhaps other SR proteins bind specifically 
to some or all purine-rich elements to promote splicing 
of weak introns, that is, introns with suboptimal splicing 
signals. On the other hand, some constitutively spliced 
introns with strong 5' and 3' splice sites and branch sites 
would not be expected to require exonic enhancer ele- 
ments for efficient splicing. Such pre-mRNAs, for exam- 
ple, B-globin, also require SF2/ASF (or other SR proteins) 
for splicing in vitro (Krainer et al. 1990a); and in these 
cases, it remains to be determined whether high-affinity 
binding sites for SF2/ASF are also required and whether 
they are located in exons or introns. 
In vitro splicing of an HIV tat pre-mRNA is strongly 
dependent on an excess of SF2/ASF (Krainer et al. 1990a). 
Examination of the nucleotide sequence of the 3' termi- 
nal exon of this substrate reveals long purine-rich seg- 
ments. This suggests that activation of otherwise weak 
tat and bGH splicing by excess SF2/ASF may have a 
similar mechanistic basis. Recently, it was shown that 
in the presence of excess competitor RNA, SF2/ASF, but 
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not SC35, can form a commitment complex with the 
same tat pre-mRNA in vitro, whereas SC35 commits 
f~-globin pre-mRNA more fficiently than SF2/ASF (Fu 
1993). The formation of a specific commitment complex 
with an SR protein in vitro is consistent with the pres- 
ence of a high-affinity binding site for that SR protein. 
hnRNP A1 counteracts SF2/ASF to promote the use of 
distal alternative 5' splice sites and also to promote cer- 
tain alternative exon skipping events (Mayeda and 
Krainer 1992; Mayeda et al. 1993). These effects are con- 
centration dependent with respect o both SF2/ASF and 
hnRNP A1. In this study we demonstrate that hnRNP 
A1 also counteracts SF2/ASF to promote alternative in- 
tron retention of bGH pre-mRNA. Thus, it appears that 
hnRNP A1 is able to antagonize SF2/ASF in a variety of 
alternative pre-mRNA splicing events, although this is 
not the case for the activity of SF2/ASF that stimulates 
proximal alternative 3' splice sites (Fu et al.-1992). 
Compared with SF2/ASF, hnRNP A1 binds with low 
specificity to the FP element, with at least fivefold lower 
selectivity between two exon 5 RNA fragments contain- 
ing or lacking the ESE. This observation does not exclude 
the possibility that hnRNP A1 recognizes certain se- 
quences with high affinity, both in bGH and in other 
pre-mRNAs. The opposing effects of hnRNP and SF2/ 
ASF on the splicing of bGH intron D could be explained 
by competition between the two proteins for overlapping 
binding sites. Alternatively, hnRNP A1 may block pro- 
tein-protein or protein-RNA interactions between SF2/ 
ASF and other splicing factors equired to recognize the 
weak 5' splice site, such as U1 snRNP. 
Previous experiments showed that specific competitor 
RNA containing the FP element inhibited splicing of 
bGH intron D but not of a control adenovirus intron. 
These results suggested that splicing of bGH intron D is 
especially sensitive to changes in the levels of the puta- 
tive splicing factor binding to the FP element (Sun et al. 
1993}. We found that addition of hnRNP A1 and SF2/ 
ASF proteins in similar amounts to those used to affect 
bGH alternative splicing had no detectable ffect on 
splicing of adenovirus and ~-globin introns. Moreover, 
the stimulatory effect of SF2/ASF addition on intron D 
removal was demonstrated in HeLa cell nuclear extract, 
where SF2/ASF is already present. Therefore, SF2/ASF 
appears to be limiting for bGH intron D splicing in vitro, 
as was shown previously to be the case for an HIV tat 
pre-mRNA that is naturally spliced inefficiently, but not 
for constitutively spliced pre-mRNAs (Krainer et al. 
1990a). Natural fluctuations of the relative levels of SF2/ 
ASF and hnRNP A1 may serve to regulate the extent o 
which an intron is retained or spliced in different issues 
or developmental stages. 
The bGH intron D has a weak 5' splice site which, 
when mutated to the mammalian 5' splice site consen- 
sus sequence, converts it into a constitutively spliced 
intron in vivo, independent of the presence of the FP 
element in the downstream exon (Dirksen et al. 1994). 
This is consistent with the notion that the selection of 
suboptimal splice sites is more sensitive to the fluctua- 
tion of certain constitutive splicing factors--in this case, 
the general splicing factor SF2/ASF (Krainer et al. 1990b; 
Dominski and Kole 1992; Mayeda et al. 1993). Moreover, 
the possible role of the FP element in compensating for a 
weak 5' splice site suggests that the mechanism of ac- 
tion of SF2/ASF in alternative intron retention of bGH 
pre-mRNA may be related to the mechanism of alterna- 
tive 5' splice site selection of internal exons. 
The exon definition model proposes that the splicing 
machinery first scans and defines the downstream exon, 
as an obligatory step in the identification of the up- 
stream intron (Robberson et al. 1990; Talerico and Berget 
1990}. Exon definition is proposed to occur through in- 
teractions between factors bound at the 3' splice site of 
the intron being removed and at the downstream 5' 
splice site (Robberson et al. 19901. Interactions defining a 
preprotachykinin alternative xon have been shown to 
include binding of U2AF 65 at the 3' splice site and of U1 
snRNP at the downstream 5' splice site, via at least one 
other protein factor bridging across the exon (Hoffman 
and Grabowski 1992). The polyadenylation signal has 
been proposed to fulfill a role analogous to that of a func- 
tional downstream 5' splice site in the case of 3'-termi- 
nal exons (Niwa nd Berget 1991). Alternatively, internal 
exon sequences with limited complementarity o U1 
snRNA, which influence splicing of the upstream intron, 
may function as the exon definition signals for the 3'- 
terminal exons (Wassarman and Steitz 1993; Watakabe 
et al. 1993). 
Our experiments suggest an additional mechanism, in 
which a protein factor mediating interaction between 
U2AF and U1 snRNP may bind directly to an element 
within the 3'-terminal exon and thus help to define the 
last exon. We showed that SF2/ASF activates plicing of 
the upstream bGH intron D through specific interaction 
with a downstream exon element, suggesting that one or 
more SR proteins, in this case, SF2/ASF, may be respon- 
sible for the recognition of 3'-terminal exons. Interest- 
ingly, the third component required to bridge the inter- 
action between U2AF and U1 snRNP across the prepro- 
tachykinin exon 4, is absent in HeLa cell S100 extract 
(Hoffman and Grabowski 1992); hence, it may be one of 
the SR proteins. Interactions between SF2/ASF and U1 
snRNP, which promote the binding of U1 snRNP to 5' 
splice sites, have been demonstrated recently (Eperon et 
al. 1993). SC35, another member of the SR protein fam- 
ily, has been found to be capable of mediating interac- 
tions between U1 and U2 snRNPs at the 3' splice site (Fu 
and Maniatis 1992). Therefore, one of the functions of SR 
proteins may be to interact with U2AF and U1 and U2 
snRNPs during exon definition and splice site selection. 
The mechanism of regulation of Drosophila dsx fe- 
male-specific alternative splicing also involves specific 
binding of proteins to a downstream exon element, and 
interestingly, the splicing enhancer complex that forms 
at this site includes SR proteins (Tian and Maniatis 
1993). The dsx exonic enhancer, which is not purine- 
rich, consists of six 13-nucleotide repeats not found in 
other genes. It is recognized by specific regulatory pro- 
teins encoded by tra and tra2, which in turn recruit SR 
proteins to form a commitment complex. In contrast, in 
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the bGH system we have shown that there is direct con- 
tact between at least one SR protein, SF2/ASF, and the 
bGH exonic enhancer, which includes purine-rich seg- 
ments. In addition, the dsx splicing commitment  com- 
plex forms more eff iciently with SC35 than with SF2/ 
ASF (Tian and Maniat is  1993), whereas bGH intron D 
splicing is st imulated by SF2/ASF but not by SC35. 
However, once the respective splicing enhancer com- 
plexes are assembled, the interact ions mediated by 
bound SR proteins, which lead to splicing activation, 
may be very similar in both cases. The idea that exonic 
enhancers operate by similar mechanisms,  aside from 
their use of specialized regulatory proteins in certain in- 
stances, is supported further by the observation that the 
purine-rich splicing enhancer from the rout ine IgM last 
exon can funct ional ly  replace the Drosophila dsx en- 
hancer, leading to act ivat ion of the upstream intron in a 
Tra/Tra2- independent manner  (Watakabe et al. 1993). 
The similar sequence composit ion and downstream 
exon location of vertebrate purine-rich splicing enhanc- 
ers, including the bGH FP element, was noted previously 
(Watakabe t al. 1993). This s imilar ity suggests that di- 
rect binding by SF2/ASF (and/or other SR proteins), 
counteracted by hnRNP A1, may be a general mecha- 
n ism for regulating alternative splicing of pre-mRNAs 
that contain purine-r ich splicing enhancers. 
Materials and methods  
Plasmid constructions 
The plasmid E5/FP contains a ll5-nucleotide FspI-PvuII re- 
striction fragment from bGH exon 5, derived from plasmid 
pbGH-4D5 (Sun et al. 1993), which was subcloned into the 
EcoRI-SmaI sites of pBS-M13 +. The plasmid E5/FPD contains 
a 135-nucleotide SmaI-EcoRI restriction fragment from the 
bGH exon 5, derived from plasmid pbGH-4DS/FPD (Sun et al. 
1993), which was subcloned into the EcoRI-SmaI sites of pBS- 
M13+. 
Splicing factors 
Human SF2/ASF (0.2 mg/ml) was purified from HeLa cell nu- 
clear extract as described {Mayeda et al. 1993). This highly pu- 
rified fraction is devoid of SG35 and other SR proteins (data not 
shown). Human recombinant hnRNP A1 (0.2 mg/ml) was ex- 
pressed in Escherichia co//and purified as described (Mayeda 
and Krainer 1992). Recombinant human SF2/ASF (0.65 mg/ml) 
was expressed in E. co//, as described (Caceres and Krainer 
1993), and purified from inclusion bodies by chromatography on 
Mono S {Pharmacia) in 6 M urea, followed by renaturation. Re- 
combinant SC35 {0.13 mg/ml) purified from baculovirus-in- 
fected insect cells was a generous gift from T. Maniatis (Harvard 
University, Cambridge, MA). Protein concentrations were de- 
termined by the dye-binding assay (Bio-Rad) with BSA as a stan- 
dard. 
Splicing reactions and UV cross-linking assays 
HeLa cell nuclear extract and S100 extract were prepared essen- 
tially as described (Dignam et al. 1983). All splicing reactions 
were performed as described (Sun et al. 1993), except hat 4 ~1 of 
nuclear extract was used in each reaction either alone or to- 
gether with purified splicing factors as indicated in Figures 3 
and 4. 
The plasmids E5/FP and E5/FPD were linearized with 
BamHI, transcribed invitro with T7 RNA polymerase, and used 
in UV cross-linking assays as described {Sun et al. 1993), except 
that the RNase A-treated cross-linked products were analyzed 
by 10% SDS-PAGE. 
UV cross-linking/immtmoprecipitation ssays 
The anti-hnRNP A1 mAb 4B10 was a generous gift from Drs. G. 
Dreyfuss and S. Pifiol-Roma (University of Pennsylvania, Phil- 
adelphia). The anti-SF2/ASF mAb and a control monoclonal 
antibody against abacterial protein will be described elsewhere; 
the anti-SF2/ASF mAb does not cross-react with other SR pro- 
teins by Western blotting {A. Hanamura nd A.R. Krainer, in 
prep.). Anti-hnRNP A1 mAb in ascites fluid {2.5 ~1) or anti-SF2/ 
ASF mAb or control monoclonal ntibody culture supernatants 
(300 ~1) were used in each immunoprecipitation reaction. Anti- 
bGH mAb (Salata et al. 1992) {2 mg/ml} was used in a preclear- 
ing step. Radiolabeled ES/FP or E5/FPD RNA was first cross- 
linked in either HeLa cell nuclear extract or SlO0 extract and 
treated with RNase A as described {Sun et al. 1993). Each reac- 
tion was precleared with S ~1 of bGH mAb and S0 ~1 of 50% 
protein A agarose in 500 ~1 of IP buffer {50 mM "Iris at pH 8.0, 
1S0 rnM NAG1, 0.05% NP-40) and mixed for 1 hr at 4~ At the 
same time, each antibody was prebound to 50 ~1 of protein 
A-agarose {50% )in 500 ~1 of IP buffer for 1 hr and washed twice 
with 1 ml of IP buffer for 15 rain at 4~ After spinning in a 
microcentrifuge for 30 rain at 4~ the supernatant was incu- 
bated further with each monoclonal antibody immobilized on 
protein A-agarose. The immunoprecipitation reactions were 
mixed at 4~ overnight. After six washes with 1 ml of IP buffer 
at 4~ each sample was eluted in 40 ~1 of 1 x sample buffer 
(62.5 mM Tris at pH 6.8, 2% SDS, 10% glycerol, 5% ~-mercap- 
toethanol) at 85~ for 10 rain and analyzed by 10% SDS-PAGE. 
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